Pharma. Wants SAC-Linked Legal Fees Covered

Apr 1 2014 | 1:42pm ET

Pharmaceutical company Elan Corp. wants some of the $1.8 billion SAC Capital Advisors hopes to pay to settle insider-trading allegations.

Elan, whose shares former SAC trader Mathew Martoma was convicted of trading illegally, has asked to be declared a victim of the scheme under federal law. Such a designation would allow it to recoup $1.5 million in legal fees it incurred while cooperating with federal probes of SAC.

“Over the course of more than three years, Elan responded to numerous requests” from the Department of Justice, Federal Bureau of Investigation and Securities and Exchange Commission “for documents, electronic data and related materials,” Elan chief legal officer Gregory Bokar said.

U.S. District Judge Laura Taylor Swain is set to consider SAC’s guilty plea to insider-trading charges on April 10. As part of that deal, SAC has agreed to cease managing outside capital and to become a family office. The firm will change its name to Point72 Asset Management three days before the hearing.


In Depth

bfinance: Fees Falling Across Asset Classes, Yet Overall Investor Costs Still Climbing

May 16 2017 | 9:53pm ET

Despite unprecedented attention on fees, new research from investment consultancy...

Lifestyle

Aston Martin Returns To Debt Market As DB11 Drives Turnaround

Mar 31 2017 | 5:21pm ET

James Bond’s preferred carmaker is returning to the public debt markets for the...

Guest Contributor

Risk-Based Compliance: Why Oversight Of Outsourcing Is Critical

May 10 2017 | 7:02pm ET

Compliance is notoriously one of the trickiest middle office functions for funds...

 

From the current issue of